CROI:
Hepatitis B Coinfection Does Not Impact HIV Suppression or CD4 Cell
Recovery on HAART
(Feb 26, 2008)
OctoPlus Initiates Phase IIa Study of Locteron
Controlled-release Interferon
(Feb 22,
2008)
CROI:
HBeAg and HBV DNA Predict Outcomes of Pegylated Interferon Therapy for
Chronic Hepatitis B (Feb 19, 2008)
SciClone and Sigma-Tau Report Interim Results from Phase
3 Trial of Thymalfasin (Zadaxin) for Non-responder Hepatitis C Patients
(Feb 15, 2008)
CROI:
Two Studies Look at Anti-HIV Activity of Entecavir (Baraclude) (Feb
12, 2008)
Migenix Adds Higher 600 mg Celgosivir Dose of Celgosivir
in Phase II Study
(Feb 12,
2008)
Overview of the Natural History of Chronic Hepatitis B (Jan 18,
2008)
Two Studies Show Telbivudine (Tyzeka) Is Superior to Lamivudine
(Epivir-HBV) for Chronic Hepatitis B
(Jan 8, 2008)
Goal of HBV treatment – Prevent resistance
(Jan 3, 2008)
Hepatitis B Clinical Research Network Starts
(Dec 4, 2007)
Hepatitis B Clinical Research Network RFA Guidelines from the National
Institute of Health (NIH) (Oct 11, 2007)
ABC News: Studies: MS, Hep B Vaccine Not Linked
(Nov 21, 2007)\
Predictors and Long-term Outcomes Associated with Hepatitis B Surface
Antigen (HBsAg) Clearance (Nov 20,
2007)
Chronic Hepatitis B Patients with Low HBV Viral Load Still Have an
Elevated Risk of Liver Cancer: R.E.V.E.A.L.-HBV Study (Nov 16,
2007)
Gender Difference in the Natural Course of HBeAg-Positive Chronic
Hepatitis B (Nov 13, 2007)
HepatitisWATCH NEWS: HBV in Asian Americans (Part 2 of a 2-part series)
(released October 2007)
Clinical Significance of Persistently Normal ALT in Chronic Hepatitis B Patient
(Oct 10, 2007)
Why we should routinely screen Asian American adults for hepatitis B: A
cross-sectional study of Asians in California
(Oct
17, 2007)
Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV (Oct 2, 2007)
HEPATITIS JOURNAL REVIEW: A Bi-Monthly Publication of the Hepatitis Support Project (Sep 25, 2007)
Omega 3 – Omega 6: What is right for the liver?
(Sep 3, 2007)
ICAAC: Cross-resistance to 3TC and FTC develops slowly with entecavir monotherapy (Sep 21, 2007)
Phase 2 of tenofovir for the treatment of HBV meets primary endpoint
(Jun 27, 2007)
Serum HBV RNA Is a Predictor of Early Emergence of Lamivudine
Resistance (Jun 22, 2007)
DDW:
Patient survey says that many hepatitis B patients stop taking meds
(May 30, 2007)
DDW:
Risk of liver-related deaths from HBV, HCV and HBV/HCV coinfection
(May 26/2007)
DDW:
Prognosis Following Hepatitis B Surface Antigen Clearance (May
25, 2007)
DDW:
Selected Telbivudine Studies Presented at DDW 2007 (May 25,
2007)
DDW:
Tenofovir Suppresses HBV in Patients Non-responsive to Adefovir, But
Not in Those with Adefovir-resistant HBV (May 25, 2007)
DDW:
Entecavir Produces Greater Viral Load Reduction Compared to Adefovir
at 48 Weeks in HBeAg-positive Patients (May 25, 2007)
DDW: AASLD presents noteworthy Research Highlights (May 21, 2007)
EASL-Effects of insulin sensitizing agents in nonalcoholic fatty liver disease, metabolics: metformin, rosiglitazone, metformin+rosiglitazone
(Apr 23, 2007)
EASL: 76 Week Follow-up of HBeAg-Positive Chronic Hepatitis B Patients Treated with Telbivudine, Adefovir or Switched from Adefovir to Telbivudine (Apr 23, 2007)
EASL: HBV rtI233V Polymerase Variant Remains Sensitive to Adefovir (Apr 23, 2007)
EASL: Pegasys Superior to Lamivudine Over 3 Years in HBV DNA Decline, ALT Normalization & HBsAg Loss (8% vs 0) & Seroconversion (4% vs 0) (Apr 23, 2007)
EASL: Peginterferon a-2a Plus adefovir vs Peginterferon a-2a for 48 Weeks in HBeAg-Negative Chronic Hepatitis B: Preliminary 24-Week Results of the PEG FOR B Randomized Multicenter Trial (Apr 23, 2007)
EASL: Efficacy of Entecavir and Lamivudine in Chronic Hepatitis B Patients with Advanced Liver Fibrosis/Cirrhosis (Apr 23, 2007)
EASL: Presence of biopsy-proven histologic damage (necroinflammation and fibrosis) is common even when ALT is less than 2 X ULN in patients with chronic hepatitis B (Apr 23, 2007)
Hepatitis B Virus Kinetics Is Similar in HIV/HBV-co-infected and
HBV-mono-infected Individuals (Feb 28, 2007)
Effect of HBV Genotype on Clinical Parameters and Response to Interferon
(Feb, 26, 2007)
Study of HBV immune response and toll-like receptors may lead to new therapies for HBV (1/12/2007)
Resistance to adefovir dipivoxil in patients with chronic hepatitis B (1/11/2007)
Valeant Pharmaceuticals and Metabasis Therapeutics License Rights to Hepatitis B Compound Pradefovir to Schering-Plough Corporation (12/11/2006)
Interferon Prevents Liver Cirrhosis and Cancer in Patients with Chronic Hepatitis B
(12/01/2006)
Different Signaling Pathways in Patients with Hepatitis B and C (12/1/2006)
News items preceded by “Drug Resistance Wksp:” is from the XV International HIV Drug Resistance Workshop
June 13-17, 2006 Sitges, Spain
News that has EASL in front of it is recent info from the European Association for the Study of the Liver conference (2006)
TYZEKA(TM) (telbivudine) Approved by U.S. Food and Drug Administration (FDA) as a New Treatment for Patients with Chronic Hepatitis B (10/25/2006)
Cost Effectiveness of Treatment Options for HBV Patients with Cirrhosis (10/10/2006)
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection (09/22/2006)
BMS Announces Baraclude (entecavir) Now Available In The UK For Treatment Of Chronic Hepatitis B - (09/21/2006)
Novartis wins first major nod for hep B drug - (09/21/2006)
Antiretroviral Therapy for Hepatitis B Virus-HIV-Coinfected Patients: Promises and Pitfalls - (09/18/2006)
Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-α2b plus ribavirin treatment in a patient with hepatitis B and C coinfection - (09/15/2006)
IAC: Safety of Atazanavir (ATV) and ATV/Ritonavir (ATV/RTV) in Patients Co-infected With HIV and Hepatitis B and/or C: 1100 Patient-years of Treatment Exposure (09/06/2006)
Risk Factors for Hepatitis Flares After Discontinuing Adefovir (06/06/2006)
Tenofovir More Potent than Adefovir Against Lamivudine-Resistant HBV (06/06/2006)
Factors Associated with Progression to Cirrhosis and Liver Cancer (06/06/2006)
DDW 2006
94% of Hepatitis B Patients Receiving Entecavir Experience Undetectable HBV Viral Load Compared to 77% of Patients Receiving Lamivudine (05/26/2006)
DDW 2006
Final Analysis of Virological Outcomes and Resistance during 5 Years of Adefovir Monotherapy. (Slide set) K. Borroto-Esoda. Abstract 477.
(05/26/2006)
DDW 2006
Impact of Adefovir in Patients with Lamivudine-resistance Undergoing Liver Transplantation.
(Slide set) . (05/26/2006)
DDW 2006
Predictive Factors for Exacerbation of Hepatitis B after Discontinuation of Adefovir.
(Slide set) (05/26/2006)
EASL: Phase II Multi-Center, Dose-Escalating study of LB80380 (ANA380) in hepatitis B Patients with Lamivudine-Resistant YMDD Mutant HBV (05/16/2006)
15% HBV Prevalence in NYC Among Asians - (05/16/2006)
EASL: HBV Resistance Determination from the Telbivudine GLOBE Registration Trial (05/16/2006)
EASL: Pharmacokinetics and Pharmacodynamics of Pradefovir Mesylate, a Liver-Targeting Pro-Drug of PMEA, in HBV Patients (05/16/2006)
EASL: Clevudine HBV drug at 48 Weeks (05/16/2006)
EASL: Safety, Tolerability and Antiviral Activity of Pradefovir Mesylate in Patients with Chronic Hepatitis B Virus Infection: 48-Week Analysis of a Phase 2 Study (05/16/2006)
